FORMULATION ARTICLES
-
The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
-
Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit
Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.
-
Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.
-
Targeted Delivery – A Holy Grail For CRISPR Gene Editing
Precise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.
-
The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety
Why LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.
-
Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success
As RNA pipelines mature, delivery success demands shared benchmarks. This article proposes standardized, stage-specific metrics to compare platforms, guide optimization, and strengthen regulatory confidence.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
We showcased the utility of microfluidics to enable low shear, rapid screening of preclinical candidates and the swift advancement to GMP-enabling studies.
-
Cell therapies, using reprogrammed immune cells, offer innovative treatments for diseases. Discover how lipid nanoparticles (LNPs) enhance these therapies by delivering RNA for gene modulation and next-gen treatments.
-
As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality.
-
Lipid nanoparticles (LNPs) have played a crucial role in COVID-19 vaccine development as efficient mRNA delivery systems, exhibiting versatility and effectiveness in accelerating the process.
-
The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.
-
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.